You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France

Drylewicz, Juliaa,b; Matheron, Sophiec; Lazaro, Estibalizd; Damond, Florencec; Bonnet, Fabriced; Simon, Françoise; Dabis, Françoisa,b; Brun-Vezinet, Françoisec; Chêne, Genevièvea,b; Thiébaut, Rodolphea,b

doi: 10.1097/QAD.0b013e3282f4ddfc
Basic Science

Background: HIV-2 is known to be less pathogenic than HIV-1, although the underlying mechanisms are still debated. We compared the changes over time in viro-immunological markers in HIV-1 and HIV-2-infected patients living in France during natural history and after initiation of the first combination antiretroviral therapy (CART).

Method: Patients were included in the ANRS CO3 HIV-1 cohort (N = 6707) or the ANRS CO5 HIV-2 cohort (N = 572). HIV-1-infected patients were matched to HIV-2 patients according to sex, age, HIV transmission group and period of treatment initiation. Changes in markers were estimated using linear mixed models.

Results: Analyses were performed for three groups of patients: those with estimated date of contamination (98 HIV-1 and 49 HIV-2-seroincident patients); untreated seroprevalent patients (320 HIV-1 and 160 HIV-2); and those initiating a first CART (59 HIV-1 and 63 HIV-2). In group 1, CD4 T-cell counts decreased less rapidly in HIV-2 than HIV-1 patients (−9 versus −49 cells/μl per year, P < 10−4). Results were similar in group 2. Baseline CD4 cell count at CART initiation was not different according to the type of infection. During the first 2 months of treatment, the CD4 cell count increased by +59 cells/μl per month (CI 34; 84) for HIV-1 and +24 (CI 6; 42) for HIV-2. The plasma viral load drop was threefold more important in HIV-1 patients: −1.56 log10/ml per month versus −0.62 among HIV-2 patients (P < 10−4).

Conclusion: Differences between the two infections during natural history are similar to those previously described in Africa. Once treatment is started, response is poorer in HIV-2 than in HIV-1 patients.

Author Information

From the aINSERM, U875 “Epidemiology and Biostatistics”, Bordeaux F-33076, France

bBordeaux 2 University, ISPED, Bordeaux F-33076, France

cBichat Claude Bernard Hospital, Assistance Publique des Hôpitaux de Paris, Paris F-75018, France

dBordeaux University Hospital, Bordeaux F-33000, France

eCharles Nicolle Hospital, Rouen F-76000, France.

Received 1 August, 2007

Revised 16 October, 2007

Accepted 26 November, 2007

Correspondence to Rodolphe Thiébaut, INSERM U897, ISPED – Université Bordeaux 2, 146 Rue Léo Saignat, 33076 Bordeaux, France. Tel: +33 5 57 57 45 21; fax: +33 5 56 24 00 81; e-mail:

© 2008 Lippincott Williams & Wilkins, Inc.